GlassScriptPhysician profile
Denise Rashti
NPI 1811022247
$1,481.97
in general payments reported to CMS, 2019-2025
13 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $96.77 · 2021: $323 · 2022: $327 · 2023: $252 · 2024: $245 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $734 · Education: $1.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $733.78 |
| Education | $1.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $799.54 | 2020-2025 | Aplenzin, Wellbutrin |
| Abbvie INC. | $124.39 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $99.62 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $77.90 | 2022-2025 | Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $76.43 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $59.64 | 2020-2022 | |
| Owp Pharmaceuticals, INC. | $58.09 | 2023-2025 | Subvenite, Lamotrigine |
| Lundbeck LLC | $47.89 | 2021-2022 | |
| Alkermes, INC. | $39.00 | 2024-2025 | Aristada, Lybalvi |
| Corium, LLC | $34.89 | 2022-2023 | Azstarys |
| Livanova USA, INC. | $30.38 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Allergan, INC. | $17.20 | 2020 | |
| Tris Pharma INC | $17.00 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Rashti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.